Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access
Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc
Journal website https://www.cardiologyres.org

Original Article

Volume 9, Number 4, August 2018, pages 224-230

Ivabradine Versus Beta-Blockers in Mitral Stenosis in Sinus Rhythm: An Updated Meta-Analysis of Randomized Controlled Trials

Figures

Figure 1.
Figure 1. Summary of search strategy.
Figure 2.
Figure 2. Summary of risk of bias assessment of the included studies.
Figure 3.
Figure 3. Forest plot showing the mean time of exercise duration with ivabradine versus beta-blocker in patients with MS in sinus rhythm.
Figure 4.
Figure 4. Forest plot showing the maximal HR achieved with ivabradine versus beta-blocker in patients with MS in sinus rhythm.
Figure 5.
Figure 5. Forest plot showing the work capacity achieved with ivabradine versus beta-blocker in patients with MS in sinus rhythm.
Figure 6.
Figure 6. Forest plot showing the mean transvalvular gradient achieved with ivabradine versus beta-blocker in patients with MS in sinus rhythm.
Figure 7.
Figure 7. Forest plot showing the resting HR achieved with ivabradine versus beta-blocker in patients with MS in sinus rhythm.

Table

Table 1. Characteristics of Included Studies
 
StudyPopulationNInterventionOutcomesMethod
Parakh et al [18]Mild-to-moderate MS, in SR (4 weeks)50Ivabradine vs. atenololMean total exercise time, max exercise HR, mean HROpen-label RCT
Saggu et al [17]Mild-to-moderate MS, in SR (6 weeks)33Ivabradine vs. metoprololResting HR, total exercise duration, mean gradientCross-over RCT
Rajesh et al [19]Moderate MS, in SR (6 weeks)82Ivabradine vs. atenololMean total exercise durationOpen-label RCT
Agrawal et al [16]Mild-severe MS, in SR (6 weeks)97Ivabradine vs. metoprololWork capacity, baseline HR, maximal HROpen-label RCT
Dhanger et al [21]Symptomatic MS, in SR (3 months)100Ivabradine vs. atenololResting HR, max HR, work capacity, total exercise duration, mean gradientRCT